July 2018 - Biologics by McKesson

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics by McKesson

Jul 23, 2018 | Press Release

CARY, N.C. (July 23, 2018) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1...

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics by McKesson

Recent Posts

Archives